title: [Second-line chemotherapy for colorectal cancer].
abstract: For the current metastatic colorectal cancer, FOLFIRI or FOLFOX is chosen as first-line chemotherapy. Second-line irinotecan-based chemotherapy is commonly used after first-line oxaliplatin-based chemotherapy. Of course, FOLFOX becomes the second-line if FOLFIRI becomes primary therapy. It is important that these regimens combine molecular targetting agents such as Bevacizumab or Cetuximab. The addition of these new agents offers a chance to further enhance the activity of conventional chemotherapy.
authors.affiliation: Hokkaido University Hospital Cancer Center, Sapporo, Japan.
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Komatsu
authors.forename: Susumu
authors.initials: S
authors.lastname: Sogabe
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kawamoto
authors.forename: Ichiro
authors.initials: I
authors.lastname: Iwanaga
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Uehata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yuki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
mesh_terms: D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D012008:Recurrence; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents